Shandong Xinhua Pharmaceutical Company Limited - Asset Resilience Ratio
Shandong Xinhua Pharmaceutical Company Limited (XIN) has an Asset Resilience Ratio of 0.64% as of December 2016. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read XIN liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2016)
This chart shows how Shandong Xinhua Pharmaceutical Company Limited's Asset Resilience Ratio has changed over time. See XIN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Shandong Xinhua Pharmaceutical Company Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shandong Xinhua Pharmaceutical Company L (XIN) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €30.00 Million | 0.64% |
| Total Liquid Assets | €30.00 Million | 0.64% |
Asset Resilience Insights
- Limited Liquidity: Shandong Xinhua Pharmaceutical Company Limited maintains only 0.64% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Shandong Xinhua Pharmaceutical Company Limited Industry Peers by Asset Resilience Ratio
Compare Shandong Xinhua Pharmaceutical Company Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Shandong Xinhua Pharmaceutical Company Limited (2016–2016)
The table below shows the annual Asset Resilience Ratio data for Shandong Xinhua Pharmaceutical Company Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2016-12-31 | 0.64% | €30.00 Million ≈ $35.07 Million |
€4.72 Billion ≈ $5.52 Billion |
-- |
About Shandong Xinhua Pharmaceutical Company Limited
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People's Republic of China, the Americas, Europe, and internationally. The company offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing service… Read more